ArticleMedicine2026
The mechanism of Qingyi decoction in improving intestinal barrier injury in pancreatitis: Network pharmacology analysis, machine-learning models, and molecular docking.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSevere acute pancreatitis (SAP) is one of the most prevalent acute abdominal conditions encountered in general surgery, often complicated by multiple organ dysfunction. In SAP, the intestine is one of the first and most severely affected organs. Intestinal barrier injury (IBI) plays a key role in disease progression and poor prognosis. Qingyi Decoction (QYD), a traditional Chinese medicine, is widely used to treat SAP clinically. Although clinical observations suggest that QYD improves IBI in patients with SAP, the underlying mechanisms remain unclear. This study aimed to evaluate QYD's multi-target mechanisms in treating SAP-associated IBI via network pharmacology and machine learning, with significance in clarifying IBI pathology and providing a technical paradigm for TCM mechanism research.
methodsThe components of QYD and the targets of IBI were identified by searching different databases. Furthermore, integrated analyses including network pharmacology, machine learning, and molecular docking were conducted using Auto Dock Vina.
resultsA total of 30 potential therapeutic targets of QYD for IBI were identified through network pharmacology and bioinformatics analyses. KEGG pathway enrichment analysis revealed significant involvement of the IL-17 signaling pathway, TNF signaling pathway, and NF-kappa B signaling pathway. Protein-protein interaction and drug-ingredient-target network analyses identified IL-6, HIF1A, and PTGS2 as primary targets. Machine-learning methods further identified IGFBP3 and Sonic Hedgehog (SHH) as hub genes. Gene set enrichment analysis (GSEA) indicated that IGFBP3 was primarily associated with the p53 signaling pathway, whereas SHH was associated with cancer-related signaling pathways. Immune infiltration analysis showed that QYD may affect immune cell infiltration in IBI through multiple targets. IGFBP3 was negatively correlated with macrophage (M0) and neutrophil infiltration, whereas SHH was positively correlated with both. Molecular docking identified 5 major active compounds targeting the hub genes: 7,8,4'-trihydroxyisoflavone, 2,6,2',4'-tetrahydroxy-6'-methoxychalcone, quercetin, scutevulin, and daucosterol.
conclusionsThe results of this study indicated that QYD ameliorates IBI through multiple targets and signaling pathways, with the p53 signaling pathway playing a key role in its therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.